1.4% SEP Increase Impacts Pharmaceutical Investment

Original Article by

Understanding the 1.4% SEP increase: why the pharmaceutical sector is urging a reconsideration of the price cap.

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here
More Articles

Dis-Chem Insurance Branding Non-Compliant says CMS

Dis-Chem health insurance branding issues raise enforcement risk for Centriq’s MyHealth products and potential disruption for policyholders.

Click Here

National Health Insurance Negotiations: SAMA Seeks NHI Talks

National Health Insurance Negotiations: SAMA meets Motsoaledi after Godongwana urges NHI litigants to seek a settlement.

Click Here

NHI Truce Talks: Godongwana Pushes Settlement On NHI

NHI truce talks could end court battles and shift focus to workable reforms for universal health coverage.

Click Here